EE05422B1 - Klaritromtsiini, rasv- ja hdrofiilse komponendi segu sisaldav farmatseutiline preparaat, meetod selle valmistamiseks ning kasutamine - Google Patents

Klaritromtsiini, rasv- ja hdrofiilse komponendi segu sisaldav farmatseutiline preparaat, meetod selle valmistamiseks ning kasutamine

Info

Publication number
EE05422B1
EE05422B1 EEP200100433A EEP200100433A EE05422B1 EE 05422 B1 EE05422 B1 EE 05422B1 EE P200100433 A EEP200100433 A EE P200100433A EE P200100433 A EEP200100433 A EE P200100433A EE 05422 B1 EE05422 B1 EE 05422B1
Authority
EE
Estonia
Prior art keywords
clarithromine
drophilic
fat
component
mixture
Prior art date
Application number
EEP200100433A
Other languages
English (en)
Estonian (et)
Inventor
Fercej Temeljotov Darja
Mohar Milojka
Salobir Mateja
Barbara Rebic Ljubomira
Opresnik Marko
Original Assignee
Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. filed Critical Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D.
Publication of EE200100433A publication Critical patent/EE200100433A/xx
Publication of EE05422B1 publication Critical patent/EE05422B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EEP200100433A 1999-02-19 2000-02-17 Klaritromtsiini, rasv- ja hdrofiilse komponendi segu sisaldav farmatseutiline preparaat, meetod selle valmistamiseks ning kasutamine EE05422B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SI9900039A SI20150A (sl) 1999-02-19 1999-02-19 Direktno stisljivi matriks za nadzorovano sproščanje celodnevne doze klaritromicina
PCT/SI2000/000002 WO2000048607A1 (en) 1999-02-19 2000-02-17 Directly compressible matrix for controlled release of single daily doses of clarithromycin

Publications (2)

Publication Number Publication Date
EE200100433A EE200100433A (et) 2002-12-16
EE05422B1 true EE05422B1 (et) 2011-06-15

Family

ID=20432410

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100433A EE05422B1 (et) 1999-02-19 2000-02-17 Klaritromtsiini, rasv- ja hdrofiilse komponendi segu sisaldav farmatseutiline preparaat, meetod selle valmistamiseks ning kasutamine

Country Status (21)

Country Link
EP (1) EP1150686B1 (el)
AT (1) ATE286736T1 (el)
AU (1) AU776912B2 (el)
BG (1) BG65324B1 (el)
CY (1) CY1107454T1 (el)
CZ (1) CZ302781B6 (el)
DE (1) DE60017361T2 (el)
DK (1) DK1150686T3 (el)
EE (1) EE05422B1 (el)
ES (1) ES2235834T3 (el)
HR (1) HRP20010684B1 (el)
HU (1) HUP0105481A3 (el)
PL (1) PL196665B1 (el)
PT (1) PT1150686E (el)
RS (1) RS50298B (el)
RU (1) RU2237480C2 (el)
SI (2) SI20150A (el)
SK (1) SK287525B6 (el)
TR (1) TR200102396T2 (el)
UA (1) UA74778C2 (el)
WO (1) WO2000048607A1 (el)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200000054A2 (tr) * 2000-01-05 2001-08-21 Sanovel İlaç San. Ve Ti̇c. Anoni̇m Şi̇rketi̇ Klaritromisin içeren sürekli salım sağlayan tablet formülasyonları.
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
IN192748B (el) * 2000-08-29 2004-05-15 Ranbaxy Lab Ltd
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
WO2003017981A1 (en) 2001-08-29 2003-03-06 Ranbaxy Laboratories Limited Controlled release formulation of clarithromycin or tinidazol
US6642276B2 (en) * 2001-10-01 2003-11-04 M/S Ind-Swift Limited Controlled release macrolide pharmaceutical formulations
SE0103369D0 (sv) * 2001-10-09 2001-10-09 Astrazeneca Ab Pharmaceutical formulation
CA2465405A1 (en) 2001-11-02 2003-05-08 Wockhardt Limited Controlled release compositions for macrolide antimicrobial agents
CA2481271A1 (en) * 2002-04-03 2003-10-09 Ranbaxy Laboratories Limited Clarithromycin formulations having improved bioavailability
US20040115262A1 (en) * 2002-07-29 2004-06-17 Frank Jao Formulations and dosage forms for controlled delivery of topiramate
US20060083759A1 (en) * 2002-07-17 2006-04-20 Aleksander Resman Stabilization of the profile of release of active substances from a formulation
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
US8062672B2 (en) 2003-08-12 2011-11-22 Shionogi Inc. Antibiotic product, use and formulation thereof
WO2005023221A1 (en) * 2003-09-05 2005-03-17 Ranbaxy Laboratories Limited Clarithromycin formulations having improved biovailability
US7943585B2 (en) * 2003-12-22 2011-05-17 Sandoz, Inc. Extended release antibiotic composition
EP1732518A1 (en) * 2004-03-24 2006-12-20 Lupin Ltd. Clarithromycin extended release formulation
EP2283824B1 (en) 2009-07-30 2017-04-19 Special Products Line S.p.A. Compositions and formulations based on swellable matrices for sustained release of poorly soluble drugs such as clarithromycin

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331803A (en) * 1980-06-04 1982-05-25 Taisho Pharmaceutical Co., Ltd. Novel erythromycin compounds
JPS60163823A (ja) * 1984-02-03 1985-08-26 Taisho Pharmaceut Co Ltd 経口投与製剤
JPS60214796A (ja) * 1984-04-06 1985-10-28 Taisho Pharmaceut Co Ltd ６−０−メチルエリスロマイシン類の製法
JPS63188621A (ja) * 1987-01-30 1988-08-04 Taisho Pharmaceut Co Ltd 矯味経口製剤
US4808411A (en) * 1987-06-05 1989-02-28 Abbott Laboratories Antibiotic-polymer compositions
IL87219A0 (en) * 1987-08-07 1988-12-30 Abbott Lab Erythromycin formulations for oral administration
JP2553882B2 (ja) * 1987-08-08 1996-11-13 富士写真光機株式会社 走査結像光学系
US5599556A (en) * 1991-12-31 1997-02-04 Abbott Laboratories Prolamine coatings for taste masking
WO1995022319A1 (en) * 1994-02-16 1995-08-24 Abbott Laboratories Process for preparing fine particle pharmaceutical formulations

Also Published As

Publication number Publication date
CY1107454T1 (el) 2012-12-19
SK11972001A3 (sk) 2002-02-05
EP1150686A1 (en) 2001-11-07
SK287525B6 (sk) 2011-01-04
HUP0105481A2 (hu) 2002-05-29
SI20150A (sl) 2000-08-31
CZ20012964A3 (cs) 2002-01-16
DK1150686T3 (da) 2005-04-04
EE200100433A (et) 2002-12-16
HUP0105481A3 (en) 2003-04-28
DE60017361T2 (de) 2005-12-22
CZ302781B6 (cs) 2011-11-02
AU2704900A (en) 2000-09-04
RS50298B (sr) 2009-09-08
HRP20010684B1 (en) 2011-01-31
EP1150686B1 (en) 2005-01-12
YU59201A (sh) 2004-07-15
PL196665B1 (pl) 2008-01-31
PT1150686E (pt) 2005-05-31
PL350419A1 (en) 2002-12-16
BG105914A (bg) 2002-05-31
WO2000048607A1 (en) 2000-08-24
AU776912B2 (en) 2004-09-23
SI1150686T1 (en) 2005-06-30
HRP20010684A2 (en) 2002-10-31
ES2235834T3 (es) 2005-07-16
TR200102396T2 (tr) 2002-01-21
DE60017361D1 (de) 2005-02-17
ATE286736T1 (de) 2005-01-15
UA74778C2 (en) 2006-02-15
RU2237480C2 (ru) 2004-10-10
BG65324B1 (bg) 2008-02-29

Similar Documents

Publication Publication Date Title
EE05422B1 (et) Klaritromtsiini, rasv- ja hdrofiilse komponendi segu sisaldav farmatseutiline preparaat, meetod selle valmistamiseks ning kasutamine
WO2001076370A3 (en) Anthelmintic combinations
WO2002041882A3 (en) Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity
WO2003002136A3 (en) Stable formulation of modified glp-1
AU4046801A (en) Cosmetic composition, especially for use on aging and/or stressed skin
NZ513810A (en) Compositions and methods for improved delivery of hydrophobic therapeutic agents
NO20025621D0 (no) Farmasöytisk sammensetning med vedvarende frigjöring for parenteral administrasjon av hydrofile forbindelser
UA37259C2 (uk) Активна речовина для одержання лікарських засобів при лікуванні дисфункціональних маткових кровотеч
CY1107819T1 (el) Φαρμακευτικη διαμορφωση της ολανζαπινης
ES2157886T3 (es) Composiciones tensioactivas y procedimientos.
HUP9602678A1 (en) 13-substituted milbemycin 5-oxime derivatives, use thereof, anthelmintic, acaricide and insecticide compositions containing these compounds as active ingredients
ES2086022T3 (es) Composiciones estables para administracion parenteral y su uso.
WO2005065639A3 (en) Novel pharmaceutical compositions
CY1108145T1 (el) Σταθερες συνθεσεις για παρεντερικη χορηγηση
WO2002024665A8 (en) Arylalkane-sulfonamides having endothelin-antagonist activity
BR9914964A (pt) Composição lìquida aquosa
KR20150084839A (ko) 기제 및 피부 외용제
EP1449435A4 (en) WORMERS
WO1997034932A3 (en) Compositions containing starch excipients
BR0015422B1 (pt) formulações de droga de liberação prolongada.
CA2395438A1 (en) Dry compositions containing hydrophobic amino acid
AR005730A1 (es) Forma de fanciclovir, procedimiento para prepararla, composiciones farmaceuticas que la contienen y metodo para el tratamiento o profilaxis deinfecciones virales y el uso de dicha forma -fanciclovir monoidrato.
DE60200317D1 (de) Formulierung mit gesteuerter Wirkstoffabgabe enthaltend Bupropion-HCI als Wirkstoff

Legal Events

Date Code Title Description
HC1A Change of owner name
HC1A Change of owner name
MM4A Lapsed by not paying the annual fees

Effective date: 20130217